Cipla USA Initiates Class III Recall of Nilotinib Capsules Due to Stability Failures, Impacting Oncology Supply
Cipla USA, Inc. has initiated a Class III nationwide recall for specific lots of Nilotinib Capsules, 150 mg, due to out-of-specification results for description and appearance under long-term stability conditions. This voluntary action, impacting a critical oncology drug, necessitates immediate review of supply chain resilience by procurement and regulatory teams to mitigate potential patient access disruptions.
FDA-Mandated Recall: Cipla USA's Nilotinib Capsules Fail Stability Specifications
Cipla USA, Inc. has initiated a Class III voluntary recall, identified as D-0381-2026, for multiple lots of its Nilotinib Capsules, 150 mg. This action, initiated on February 18, 2026, stems from critical out-of-specification (OOS) results observed during 6-month long-term stability testing. Specifically, the product failed both the description test and the appearance by visual inspection test, indicating a degradation in the physical characteristics of the capsules over time. For procurement directors, this signifies an immediate need to quarantine and return affected inventory, specifically lots 5GJ0220, 5GJ0221, and 5GJ0222, which carry an expiration date of April 30, 2027. The nationwide distribution pattern across the U.S.A. means that any entity involved in the supply chain for these specific Nilotinib products must act decisively. Regulatory affairs heads should review their internal quality agreements with Cipla USA and its manufacturing arm, Cipla Ltd. in Verna, Goa, India, to understand the root cause analysis and corrective and preventive actions (CAPA) being implemented. Failure to address these stability issues can lead to product efficacy concerns and patient safety risks, potentially impacting treatment outcomes for patients relying on this Bcr-Abl Tyrosine Kinase Inhibitor.
Product and Manufacturer Profile: Nilotinib's Role and Cipla's Global Oncology Presence
The recalled product, Nilotinib Capsules, 150 mg, is a human prescription drug (NDA218922) classified as a Kinase Inhibitor, specifically targeting Bcr-Abl Tyrosine Kinase. It is crucial in oncology for treating certain types of leukemia. Cipla USA, Inc., based in Warren, NJ, markets this product, which is manufactured by Cipla Ltd. in Verna, Goa, India. The affected packaging includes various NDC codes such as 69097-031-74 (outer carton of 112 capsules), 69097-031-56 (inner carton of 28 capsules), and 69097-031-17 (foil blister). The recall impacts 271 cartons of the product. For business development executives, this event underscores the inherent risks in global pharmaceutical supply chains, particularly for high-value oncology drugs. Cipla, a significant player in the generics market, often serves as a key supplier for various therapeutic areas. This recall, while Class III, highlights the imperative for rigorous quality oversight at manufacturing sites, even for established global pharmaceutical companies. Supply chain VPs must recognize that even seemingly minor aesthetic changes can signal deeper formulation or manufacturing process issues that could escalate into more severe regulatory actions or broader supply disruptions if not thoroughly investigated and remediated.
Supply Chain Exposure: Mitigating Disruption for Critical Oncology Therapeutics
The nationwide distribution of Cipla USA's Nilotinib Capsules means that hospitals, pharmacies, and distributors across the U.S.A. are directly exposed to this recall. Given Nilotinib's role as a Bcr-Abl Tyrosine Kinase Inhibitor in oncology, any disruption, even from a Class III recall, can have significant implications for patient care continuity. Procurement directors must immediately assess their current stock levels of Cipla USA's Nilotinib and identify any affected lots within their inventory. The recall of 271 cartons, while not a massive volume in the broader market, represents a critical gap for those relying on these specific lots. This event mandates a proactive review of supplier qualification processes, particularly for products manufactured offshore. Business development executives should evaluate their market share and competitive positioning in the oncology segment, as this recall could create opportunities for alternative suppliers to gain market traction if Cipla's remediation is prolonged or perceived as insufficient. Furthermore, regulatory affairs teams should prepare for increased scrutiny on their own quality assurance programs, as the FDA often broadens its oversight following significant recalls within a therapeutic class.
Navigating Alternative Sourcing for Nilotinib and Kinase Inhibitor APIs
While the ChemLifeIntel Knowledge Graph does not currently list specific alternative suppliers for Nilotinib, this recall by Cipla USA, Inc. serves as a critical trigger for procurement teams to diversify their sourcing strategies for this molecule and other essential kinase inhibitors. Procurement directors should initiate a comprehensive search for qualified alternative manufacturers, focusing on those with a proven track record of FDA compliance and robust stability data. Key considerations include the geographic diversity of manufacturing sites to mitigate regional supply chain risks, as the affected product was manufactured in Verna, Goa, India. Qualification timelines for new API or finished product suppliers can range from 12 to 24 months, making early identification and engagement paramount. Business development executives should identify potential partners or acquisition targets that possess strong manufacturing capabilities for complex oncology APIs. This proactive approach minimizes reliance on a single supplier and builds resilience against unforeseen quality events, ensuring uninterrupted access to vital medications. Regulatory affairs must also evaluate the regulatory filing implications of switching suppliers, including potential comparability studies and submission requirements to the FDA.
Broader Regulatory Landscape: Persistent Quality Control Challenges in Pharma
Cipla USA's Nilotinib recall, driven by stability failures, aligns with a concerning trend of quality control challenges observed across the pharmaceutical industry in 2026. Recent parallel events highlight this persistent vulnerability. For instance, Essential Wellness Pharma faced an FDA Class II recall for Progesterone Injection due to sterility assurance issues, reported on June 15, 2026. Similarly, Spectra Medical Devices initiated a Class II recall for Lidocaine HCl Injection, also due to sterility deficiencies, on June 10, 2026. Guardian Drug Co. Inc.'s nationwide Class II recall for Tums Antacid due to metallic contamination, also on June 10, 2026, further underscores the diverse nature of quality lapses. Moreover, Sun Pharmaceutical's Fluocinonide recall in April 2026 signaled ongoing quality control challenges for another major generic player. For supply chain VPs and regulatory affairs heads, these incidents collectively emphasize the critical need for enhanced supplier auditing, robust quality management systems, and proactive risk assessments. The recurring nature of these events, spanning various product types and manufacturers, indicates systemic pressures on quality control within the global pharmaceutical supply chain, demanding a more vigilant and integrated approach to risk mitigation.
Operational Response and Future Outlook for Cipla USA and Affected Supply Chains
The Class III recall of Nilotinib Capsules by Cipla USA, Inc. is currently classified as 'Ongoing,' indicating that the firm is actively managing the recall process, including notifying customers and retrieving affected product lots. For procurement directors, this means continued vigilance and communication with Cipla USA regarding the progress of the recall and the availability of unaffected inventory or future compliant batches. The manufacturer, Cipla Ltd. in Verna, Goa, India, will be under pressure to conduct a thorough root cause analysis to identify why the Nilotinib capsules exhibited out-of-specification results for description and appearance at the 6-month stability mark. This will likely involve scrutinizing formulation, manufacturing processes, packaging, and storage conditions. Regulatory affairs teams should anticipate potential increased scrutiny from the FDA on Cipla's quality systems and manufacturing practices, which could extend beyond Nilotinib to other products. While a Class III recall typically carries a lower immediate health risk compared to Class I or II, repeated quality issues can erode trust and lead to more severe regulatory actions, including potential import alerts for the manufacturing facility if systemic issues are identified and not adequately addressed. Business development executives should monitor Cipla's response closely, as effective and transparent remediation can help restore market confidence and minimize long-term commercial impact.